ArticlePharmacological research2026
Mechanistic insights into CAR-mediated repression of the HNF4α-FABP1 axis and inhibition of HepG2 cell proliferation.
Article in Pharmacological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights.Pharmacological research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The constitutive androstane receptor (CAR) modulates the transcription of numerous genes involving drug metabolism, energy homeostasis, and cell proliferation. While rodent studies suggest an oncogenic role for murine CAR in liver cancer development, emerging evidence indicates that human CAR (hCAR) may exhibit a tumor-suppressive role in hepatocellular carcinoma; notably, overexpressing hCAR suppresses human hepatoma cell proliferation. Yet, the molecular mechanisms whereby hCAR suppresses hepatoma cell proliferation are poorly understood. Our recent RNA-seq analysis of human hepatoma cells revealed that fatty acid binding protein 1 (FABP1), a pleiotropic modulator of lipid metabolism and cancer progression, was a top gene downregulated by hCAR. Here, we report a molecular mechanism whereby hCAR downregulates FABP1 expression by modulating HNF4α signaling. Knocking down hCAR expression in a HepG2-hCAR stable cell line restores the suppressed expression of FABP1 and HNF4α, while knocking down HNF4α alone is sufficient to suppress FABP1 expression. Luciferase reporter assays revealed concentration-dependent hCAR suppression of HNF4α-mediated FABP1 transactivation. This inhibitory crosstalk between hCAR and HNF4α was further confirmed by chromatin immunoprecipitation assays, where hCAR decreased HNF4α occupancy of the FABP1 promoter. Mechanistically, hCAR inhibits HNF4α expression by prompting deacetylation of histone H3 in the HNF4α P1 enhancer region, resulting in a repressive chromatin configuration and reduced HNF4α transcription. Furthermore, overexpressing FABP1 partially rescued hCAR-suppressed cell growth. Collectively, these results uncover the hCAR-HNF4α-FABP1 axis as a novel mechanism underlying hCAR-mediated gene repression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.